AbbVie的癌症药物Venetoclax在骨髓增生异常综合征的三期联合试验中未达预期效果-动脉网

AbbVie's Cancer Drug Venetoclax Falls Short In Phase 3 Combination Trial For Myelodysplastic Syndromes

benzinga 等信源发布 2025-06-17 10:43



可切换为仅中文







AbbVie Inc

艾伯维公司

ABBV

艾伯维公司

on Monday announced an update from the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine for newly diagnosed higher-risk

周一宣布了全球三期VERONA试验的更新，该试验评估了维奈托克与阿扎胞苷联合用于新诊断的高风险患者的疗效。

myelodysplastic syndrome (HR-MDS)

骨髓增生异常综合征（高危MDS）

。

MDS is a group of cancers in which the bone marrow doesn’t produce enough healthy blood cells.

MDS是一组骨髓无法产生足够健康血细胞的癌症。

The primary outcome measure is overall survival (OS). Key secondary outcome measures include a modified overall response (mOR)

主要结局指标是总生存期（OS）。关键的次要结局指标包括修正的总体反应（mOR）。

and complete remission (CR)

完全缓解 (CR)

。

Also Read:

另请参阅：

AbbVie Scores FDA Approval For Its Blockbuster Drug Rinvoq To Treat Type Of Arthritis

AbbVie的重磅药物Rinvoq获FDA批准用于治疗某种类型的关节炎

The trial did not meet the primary endpoint of overall survival (OS) with a hazard ratio (HR) of 0.908; stratified log-rank, p=0.3772. No new safety signals were observed.

该试验未达到总生存期（OS）的主要终点，风险比（HR）为0.908；分层log-rank检验，p=0.3772。未观察到新的安全性信号。

Results from the VERONA trial will be available in a future medical congress and/or publication.

VERONA试验的结果将在未来的医学大会和/或出版物中公布。

The treating physician will inform any patients who received venetoclax in combination with azacitidine through participation in the MDS clinical trials.

主治医生将通知任何通过参与MDS临床试验接受维奈托克联合阿扎胞苷治疗的患者。

These data do not impact any currently approved indications for venetoclax.

这些数据不会影响 venetoclax 的任何当前已批准的适应症。

In the first quarter, AbbVie reported Venclexta’s revenues were $665 million,

第一季度，艾伯维报告称，Venclexta的营收为6.65亿美元，

up 8.3% year over year (+12.3%)

同比上涨8.3%（+12.3%）

。

Last week, the U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie’s Mavyret (glecaprevir/pibrentasvir) to include treatment of acute hepatitis C virus (HCV) infection in patients without cirrhosis

上周，美国食品和药物管理局（FDA）批准了艾伯维公司Mavyret（格列卡韦/匹布他韦）的标签扩展，以包括对无肝硬化患者的急性丙型肝炎病毒（HCV）感染的治疗。

or with compensated cirrhosis.

或伴有代偿性肝硬化。

With this approval, Mavyret is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate.

通过此项批准，Mavyret 成为首个也是唯一一个在八周内治疗急性丙型肝炎病毒（HCV）患者且治愈率达到 96% 的直接抗病毒药物 (DAA) 疗法。

HCV is a highly infectious blood-borne disease affecting the liver.

丙型肝炎是一种高度传染性的血源性疾病，会影响肝脏。

AbbVie Stock Prediction For 2025

艾伯维股票2025年预测

Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.

华尔街内外的股票研究分析师通常使用盈利增长和基本面研究作为估值和预测的一种形式。但许多交易者转向技术分析，以此建立股价走势的预测模型。

Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at AbbVie, an investor could make an assessment about a stock’s long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line.

一些投资者通过趋势来帮助预测他们认为某只股票在未来某个时点可能的交易价格。以艾伯维为例，投资者可以使用移动平均线和趋势线来评估一只股票的长期前景。如果他们认为股票将保持在移动平均线之上（许多人认为这是看涨信号），他们可以使用趋势线将这一趋势延续到未来。

For AbbVie, the 200-day moving average sits at $188.78, according to .

据数据显示，AbbVie 的 200 日移动平均线为 188.78 美元。

Benzinga Pro

, which is below the current price of $189.54. For more on charts and trend lines,

，低于当前价格189.54美元。有关图表和趋势线的更多信息，

see a description here.

请参见此处的描述。

Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.

交易者认为，当股票高于其移动平均线时，通常是一个看涨信号，而当它跌破移动平均线时，则是一个更负面的信号。如果条件保持稳定，投资者可以使用趋势线来对股票未来可能的交易水平做出有根据的预测。

Price Action:

价格走势：

ABBV stock is trading lower by 1.47% to $188.06 at last check Tuesday.

ABBV股票在周二最后一次交易时下跌1.47%，至188.06美元。

加载中...